P
Patrick G. Bray
Researcher at Liverpool School of Tropical Medicine
Publications - 109
Citations - 7866
Patrick G. Bray is an academic researcher from Liverpool School of Tropical Medicine. The author has contributed to research in topics: Plasmodium falciparum & Chloroquine. The author has an hindex of 51, co-authored 109 publications receiving 7540 citations. Previous affiliations of Patrick G. Bray include University of Liverpool.
Papers
More filters
Journal ArticleDOI
Artemisinins target the SERCA of Plasmodium falciparum
Ursula Eckstein-Ludwig,Richard Webb,I. D. A. van Goethem,J M East,Anthony G. Lee,Masatsugu Kimura,Paul M. O'Neill,Patrick G. Bray,Stephen A. Ward,Sanjeev Krishna +9 more
TL;DR: It is shown that artemisinins, but not quinine or chloroquine, inhibit the SERCA orthologue (PfATP6) of Plasmodium falciparum in Xenopus oocytes with similar potency to thapsigargin (another sesquiterpene lactone and highly specific SERCA inhibitor).
Journal ArticleDOI
4-Aminoquinolines—Past, present, and future; A chemical perspective
TL;DR: This review describes structure-activity relationships for the 4-aminoquinolines, along with views on the mechanism of action and parasite resistance, and potential approaches to the design of new synthetic derivatives.
Journal ArticleDOI
Pentamidine uptake and resistance in pathogenic protozoa: past, present and future
TL;DR: Progress in elucidating the mechanisms of diamidine transport in three important protozoan pathogens, Trypanosoma brucei, Leishmania and Plasmodium falciparum, is reviewed, and the implications for drug resistance are discussed.
Journal ArticleDOI
Access to Hematin: The Basis of Chloroquine Resistance
TL;DR: The model is consistent with a resistance mechanism that acts specifically at the food vacuole to alter the binding of chloroquine to hematin rather than changing the active transport of chlorquine across the parasite plasma membrane.
Journal ArticleDOI
A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance
Viswanathan Lakshmanan,Patrick G. Bray,Dominik Verdier-Pinard,David J. Johnson,Paul Horrocks,Rebecca A. Muhle,George E Alakpa,Ruth H Hughes,Steve A. Ward,Donald J. Krogstad,Amar Bir Singh Sidhu,David A. Fidock +11 more
TL;DR: Findings establish PfCRT K76T as a critical component of CQR and suggest that CQ access to ferriprotoporphyrin IX is determined by drug–protein interactions involving this mutant residue.